TIVORBEX Drug Patent Profile

✉ Email this page to a colleague

When do Tivorbex patents expire, and when can generic versions of Tivorbex launch?

Tivorbex is a drug marketed by Genus and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-seven patent family members in twenty-one countries.

The generic ingredient in TIVORBEX is indomethacin. There are fifteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the indomethacin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tivorbex

A generic version of TIVORBEX was approved as indomethacin by CHARTWELL MOLECULES on August 6^th, 1984.

Try a Trial

Summary for TIVORBEX

International Patents:	37
US Patents:	3
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	164
Clinical Trials:	2
Patent Applications:	4,362
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for TIVORBEX
What excipients (inactive ingredients) are in TIVORBEX?	TIVORBEX excipients list
DailyMed Link:	TIVORBEX at DailyMed

Drug patent expirations by year for TIVORBEX

Recent Clinical Trials for TIVORBEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sen-Jam Pharmaceutical	Phase 2
National University, Singapore	Phase 2
Iroko Pharmaceuticals, LLC	Phase 2

See all TIVORBEX clinical trials

US Patents and Regulatory Information for TIVORBEX

TIVORBEX is protected by three US patents.

Patents protecting TIVORBEX

Formulation of indomethacin
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

Formulation of indomethacin
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF PAIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genus	TIVORBEX	indomethacin	CAPSULE;ORAL	204768-001	Feb 24, 2014		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Genus	TIVORBEX	indomethacin	CAPSULE;ORAL	204768-002	Feb 24, 2014		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Genus	TIVORBEX	indomethacin	CAPSULE;ORAL	204768-001	Feb 24, 2014		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y			⤷ Try a Trial
Genus	TIVORBEX	indomethacin	CAPSULE;ORAL	204768-001	Feb 24, 2014		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y			⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for TIVORBEX

See the table below for patents covering TIVORBEX around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
New Zealand	595986	A novel formulation of indomethacin	⤷ Try a Trial
South Korea	101743847		⤷ Try a Trial
Israel	247034	תכשיר של אינדומטאצין (Formulation of indomethacin)	⤷ Try a Trial
South Korea	20120101285	A NOVEL FORMULATION OF INDOMETHACIN	⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Summary for TIVORBEX

Recent Clinical Trials for TIVORBEX

Patents protecting TIVORBEX

Make Better Decisions: Try a trial or see plans & pricing